Skip to main content

Table 3 Incidence of hematologic adverse events before/after palbociclib dose reduction from 100 to 75 mg

From: Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Adverse eventBefore dose reduction (N = 105)After dose reduction
Cycle 1 (N = 105)Cycle 2 (N = 98)Cycle 3 (N = 94)Cycle 4 (N = 88)Cycle 5 (N = 80)Cycle 6 (N = 73)
Grade, n (%)Grade, n (%)Grade, n (%)Grade, n (%)Grade, n (%)Grade, n (%)Grade, n (%)
All34All34All34All34All34All34All34
Leukopenia*36 (34.3)23 (21.9)029 (27.6)12 (11.4)026 (26.5)8 (8.2)022 (23.4)6 (6.4)021 (23.9)6 (6.8)016 (20.0)5 (6.3)017 (23.3)6 (8.2)0
Thrombocytopenia15 (14.3)3 (2.9)012 (11.4)0011 (11.2)006 (6.4)006 (6.8)006 (7.5)006 (8.2)00
Anemia11 (10.5)4 (3.8)013 (12.4)3 (2.9)011 (11.2)2 (2.0)011 (11.7)1 (1.1)09 (10.2)007 (8.8)005 (6.8)1 (1.4)0
Febrile neutropenia1 (1.0)1 (1.0)00000000000001 (1.3)1 (1.3)0000
  1. *Leukopenia includes the following preferred terms: leukopenia or white blood cell count decreased
  2. Thrombocytopenia includes the following preferred terms: platelet count decreased or thrombocytopenia
  3. Anemia includes the following preferred terms: anemia or hematocrit decreased or hemoglobin decreased